You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Colorcon
Express Scripts
Medtronic

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MEK162

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for MEK162?

MEK162 is an investigational drug.

There have been 58 clinical trials for MEK162. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Pfizer.

There are sixty US patents protecting this investigational drug and six hundred and thirty-one international patents.

Recent Clinical Trials for MEK162
TitleSponsorPhase
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesNational Cancer Institute (NCI)Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesSouthwest Oncology GroupPhase 2
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaNational Cancer Institute (NCI)Phase 2

See all MEK162 clinical trials

Clinical Trial Summary for MEK162

Top disease conditions for MEK162
Top clinical trial sponsors for MEK162

See all MEK162 clinical trials

US Patents for MEK162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEK162   Start Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
MEK162   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
MEK162   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
MEK162   Start Trial Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. (Research Park Triangle, NC)   Start Trial
MEK162   Start Trial Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors GI Therapeutics, Inc. (Research Triangle Park, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEK162

Drugname Country Document Number Estimated Expiration Related US Patent
MEK162 Argentina 077975 2029-08-28   Start Trial
MEK162 Australia 2010286569 2029-08-28   Start Trial
MEK162 Canada 2771775 2029-08-28   Start Trial
MEK162 Chile 2012000340 2029-08-28   Start Trial
MEK162 China 102725283 2029-08-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Colorcon
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.